Mounjaro Cost 2026: What You'll Actually Pay
List price is $1,112.16 per month, uniform across all dose strengths. Actual cost depends on insurance and FDA indication.
Mounjaro list price is $1,112.16 per 28-day supply, the same for every dose strength (2.5 mg through 15 mg). Commercial insurance patients whose plan covers Mounjaro for type 2 diabetes pay as low as $25 per month with the Savings Card. Patients with commercial insurance but no Mounjaro coverage pay as low as $499 per month with the same card. Federal insurance plans (Medicare, Medicaid, Tricare, VA) are excluded from the card, though Medicare Part D often covers Mounjaro for diabetes with prior authorization. Uninsured patients pay $995 to $1,294 per month retail; Mounjaro does not have a cash-pay program. Patients seeking tirzepatide for weight loss should consider Zepbound, which lists at $299 to $449 per month through LillyDirect Self Pay.
Looking for tirzepatide for weight loss? Use Zepbound, not Mounjaro.
Mounjaro and Zepbound contain the same active ingredient (tirzepatide) at the same doses. The difference is FDA approval: Mounjaro is approved for type 2 diabetes, Zepbound is approved for weight loss. Insurance rarely covers Mounjaro for off-label weight loss, forcing patients to pay $995+ per month retail. Zepbound offers a LillyDirect Self Pay program at $299-$449/month, which Mounjaro does not. If your goal is weight loss, talk to your prescriber about Zepbound instead.
What you pay, by scenario
The four common payment paths. Every price assumes the prescription is for FDA-approved use (type 2 diabetes).
Savings Card applies at retail pharmacy. Up to 13 fills per calendar year. Must be FDA-approved use (type 2 diabetes).
Savings Card at the non-covered rate. Still cheaper than retail but significantly more than the covered rate. File a formulary exception appeal if possible.
Federal plans excluded from Savings Card. Medicare Part D may cover Mounjaro for type 2 diabetes with prior authorization. Medicaid varies by state. MFN framework expected to cap Medicare copays at approximately $50/mo mid-2026.
Mounjaro has no cash-pay program. Retail pricing with GoodRx or SingleCare reduces cost but remains high. For weight loss, Zepbound ($299 to $449/mo via LillyDirect) is the clear affordability winner.
Mounjaro list price by dose
Unlike some GLP-1 drugs, Mounjaro's list price is the same across every dose strength. The amount you actually pay depends entirely on insurance and the program you qualify for, not the dose.
Why every dose costs the same at list
Eli Lilly prices Mounjaro uniformly across all dose strengths. A 4-pen pack of 2.5 mg starter pens has the same WAC as a 4-pen pack of 15 mg maintenance pens: $1,112.16. Your pharmacy retail price varies based on their markup, not the dose. This is different from Zepbound, where Lilly charges tiered prices on the LillyDirect Self Pay program. For covered patients on the Savings Card, the $25 rate applies to any dose.
Recent pricing news
Federal pricing framework and list-price updates affecting Mounjaro.
- November 6, 2025In progress
Most-Favored-Nation (MFN) pricing framework announced
Trump administration struck a deal with Eli Lilly and Novo Nordisk to lower GLP-1 prices. Impact for Mounjaro: Medicare price expected at approximately $245/month, with copays capped around $50/month for eligible beneficiaries. Coverage expected to roll out middle of 2026. TrumpRx direct-to-consumer platform launching early 2026 with GLP-1s at approximately $350/month.
Status: Announced and in implementation. Medicare and Medicaid pricing rules updating through 2026.
- January 1, 2026
List price increase to $1,112.16
Lilly updated the WAC list price for Mounjaro from $1,069.08 to $1,112.16 per 28-day supply as of January 1, 2026. This is the manufacturer wholesale price, not the patient out-of-pocket cost.
Related guides
Pricing verified against Eli Lilly's official pricinginfo.lilly.com and mounjaro.lilly.com pages, cross-referenced with GoodRx, Noom, Drugs.com, and AARP reporting. We do not accept payment for inclusion in any comparison. Medical content reviewed by Dr. Golsa Gholampour, MD, board-certified in obesity medicine. Quarterly re-verification scheduled.